Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer is the leading cause of death among Hispanics/Latinos in the US. Through more public education, community resources and access to care, survival rates are improving.
Breast cancer is the leading cause of cancer death among Hispanic/Latino women. Local community outreach programs have a direct impact on woman being diagnosed and receiving treatment earlier.
Lung cancer is the leading cause of cancer death among Hispanic/Latino men. With strong public messaging, smoking rates are starting to drop in Latino communities.
Taking up the fight to change the Latino cancer landscape are the many dedicated agencies serving their communities throughout the country. Locate the one nearest you HERE.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
Melanoma, an aggressive form of skin cancer that accounts for 75% of all skin-cancer-related deaths, is often detected later in people with darker skin complexions -- and the consequences can be devastating, a new study reveals.
Researchers have identified molecular and genetic pathways that direct the generation and maturation of parietal cells, the only cells in the body that produce acid, from stem cells. The findings can lead to new strategies to regulate parietal cell function in different diseases involving these cells, including autoimmune gastritis and stomach and esophageal cancers.
Scientists reveal how ETV4 controls stem cell differentiation in response to mechanical cues.
Researchers present Tripath: new, deep learning models that can use 3D pathology datasets to make clinical outcome predictions. The research team imaged curated prostate cancer specimens, using two 3D high-resolution imaging techniques. The models were then trained to predict prostate cancer recurrence risk on volumetric human tissue biopsies. By comprehensively capturing 3D morphologies from the entire tissue volume, Tripath performed better than pathologists and outperformed deep learning models that rely on 2D morphology and thin tissue slices.
Researchers have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors -- an advance that could transform cancer treatment. The promising findings involve CAR-T cell therapy, which supercharges the immune system to identify and attack cancer cells.
Investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival. The study provides both mechanistic and preclinical evidence supporting the rapid initiation of clinical trials for patients with acute myeloid leukemia (AML) to test an existing medicine that inhibits the complex, called eganelisib, both alone and in combination with the most used AML chemotherapy, cytarabine.